CompletedNot Applicable

Evaluation of the Prognostic Value of Immature Platelet Fraction

France196 participantsStarted 2023-04-28

Plain-language summary

Sepsis is a public health issue responsible for six million deaths worldwide each year. It is one of the leading causes of admission and morbidity and mortality in critical care. Its most severe form, septic shock, is responsible for a picture of multiple organ failure syndrome with a high mortality rate estimated at 38%. It appears important to identify routinely available and low-cost biomarkers to identify patients at risk of adverse outcomes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any adult patient admitted to critical care for sepsis defined by a SOFA score \> or = 2 or an increase of at least 2 points if there was organ dysfunction pre-existing to the infection. * For the inflammatory control group, we will include adult patients who have required extracorporeal circulation for more than 1 hour for cardiac surgery. * Patients who have read and understood the information letter and do not object to participating in the study * Patients affiliated with a social security scheme * Exclusion Criteria: * Patient refusal * Pregnant, parturient, or breastfeeding woman * Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection/guardianship or curatorship * Person who does not understand or speak French * Moribund * Febrile aplasia * Hematological diseases * Decompensated cirrhosis * Ongoing chemotherapy

What they're measuring

Evaluation of the impact of the immature platelet fraction of patients admitted to intensive care for sepsis or septic shock on their prognosis at day 28.

Timeframe: Days 28

Evaluation of the impact of the immature platelet fraction of patients admitted to intensive care for sepsis or septic shock on their prognosis at day 28.

Timeframe: Days 28

Trial details

NCT IDNCT07039227

SponsorUniversity Hospital, Rouen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-06-01

View on ClinicalTrials.gov More Septic Shock trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Evaluation of the impact of the immature platelet fraction of patients admitted to intensive care for sepsis or septic shock on their prognosis at day 28.

Timeframe: Days 28

Evaluation of the impact of the immature platelet fraction of patients admitted to intensive care for sepsis or septic shock on their prognosis at day 28.

Timeframe: Days 28